Mike Doustdar, president and CEO of Novo, expressed enthusiasm about the collaboration with Anthropic, highlighting how this partnership will enhance their R&D capabilities and advance their mission to develop innovative treatments for chronic diseases. The Danish pharmaceutical company, previously known as Novo Nordisk, officially announced the alliance on September 16, aiming to leverage Anthropic’s Claude Science technology to boost drug discovery processes.
Back
